The Disability Rights Section of the U.S. Department of Justice Civil Rights Division sent a letter to the Pennsylvania State Court System, advising them that following an investigation, several of their county court systems were found to have violated federal disability discrimination laws. I just happened to come across this and hadn’t seen it in the news anywhere. But this seems important. This has been happening in West Virginia for years, and no doubt is happening across the country.
The Justice Department found that the Unified Judicial System of Pennsylvania, through the actions of its component courts, violated the Americans with Disabilities Act (ADA) by prohibiting or limiting the use of disability-related medication to treat Opioid Use Disorder (OUD) by individuals under court supervision.
The Justice Department identified three specific individuals with OUD who had been discriminated against by the Northumberland and Jefferson County Courts of Common Pleas. Two individuals alleged that the Jefferson County Court ordered all probationers to stop using their prescribed medication for OUD. A third individual alleged that the Northumberland County Court required her to stop using her prescribed OUD medication to graduate from drug court. The department’s investigation corroborated these allegations and additionally found evidence that multiple other county courts in Pennsylvania have treatment court policies that discriminate against individuals with OUD.
According to the U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA): “OUD medication gives people the time and ability to make necessary life changes associated with long-term remission and recovery,” “minimizes cravings and withdrawal symptoms,” and “lets people better manage other aspects of their life, such as parenting, attending school, or working.”
Methadone, naltrexone, and buprenorphine (including brand names Subutex and Suboxone) are medications approved by the Food and Drug Administration to treat OUD. According to the U.S. National Institute on Drug Abuse (NIDA), methadone and buprenorphine help diminish the effects of physical dependency on opioids, such as withdrawal symptoms and cravings, by activating the same opioid receptors in the brain targeted by prescription or illicit opioids without producing euphoria.
Here’s the full letter:
I have to wonder what other applications or consequences this may have going forward?